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Adeno-associated virus preferentially transduces
human compared to mouse synovium
K Jennings, S Katakura, H Burstein, G Gao, JM Wilson, R Hirsch
Division of Rheumatology, Children’s Hospital Medical Center,
Cincinnati, OH 45229, USA; Institute for Human Gene Therapy,
University of Pennsylvania Health System, Philadelphia, PA 19104,
USA; Targeted Genetics Corp, Seattle, WA 98101, USA
There is increasing interest in adeno-associated virus (AAV)
vectors for a wide variety of gene therapy applications. AAV is a
nonpathogenic human parvovirus that can mediate long-term trans-
duction of a number of cell types without provoking a significant
immune response. These properties make AAV especially attrac-
tive for use in gene therapy of rheumatoid arthritis (RA), a chronic
inflammatory disease. To investigate the potential of AAV in gene
therapy of arthritis, the ability of AAV to infect synovium in vitro and
in vivo was tested. Three human RA synovial fibroblast cell lines
and two murine (one DBA/1J and one DBA1J×C3H F1) synovial
fibroblast cell lines were used to test AAV transduction in vitro. The
cell lines (2×105 cells) were infected with 104 particles/cell of a
murine IL-10-encoding vector (AAV-mIL-10) alone or with the addi-
tion of a low titer (100 particles/cell) of an E1-, E3-deleted recom-
binant adenovirus to provide E4orf6 activity to enhance
second-strand synthesis. The supernatants were harvested from
the wells at various time points and assayed for mIL-10 expression
by ELISA. Both human synovial cell lines infected with AAV alone
demonstrated low-level transgene expression throughout the
course of the study. However, by day 10, all human cultures coin-
fected with adenovirus showed a 16- to 56-fold increase in mIL-10
compared to cultures infected with AAV-mIL10 alone. By day 30, a
31- to 135-fold increase was observed. No such increase was
observed in any of the mouse cell lines. To determine the AAV
transduction efficiency for synovium in vivo, human RA synovial
tissues obtained from patients undergoing joint-replacement
surgery were implanted subcutaneously on the backs of
NOD.CB17-Prkdc SCID mice. After allowing a 2-week period for
engraftment, tissues were injected with 3.4×1011 particles of
AAV-luciferase alone or in combination with 1.0×1011 particles of
adenovirus. Two weeks following AAV administration, the tissues
were homogenized and assayed for expression of luciferase. Only
the tissues coinfected with adenovirus had luciferase levels above
background. A similar experiment with AAV-LacZ demonstrated
X-gal staining only of synovial tissues coinfected with adenovirus.
These findings demonstrate a preferential ability of AAV to trans-
duce human, compared to mouse, synovial tissue and suggest that
second strand synthesis may be a limiting factor in gene transduc-
tion. Further studies to elucidate the mechanisms limiting gene
transduction in human synovium may allow optimization of this
vector for the treatment of arthritis.
P2
Delivery of antisense constructs and ribozymes to
inhibit cartilage destruction in the SCID mouse
model of RA
T Pap*†, J Schedel†, U Müller-Ladner†‡, RE Gay†, W Zacharias§,
S Gay†
*Department of Experimental Rheumatology, University Hospital
Magdeburg, Germany; †WHO Collaborative Center for Molecular
Biology and Novel Therapeutic Strategies in Rheumatic Diseases,
Department of Rheumatology, University Hospital Zurich, Switzerland;
‡Department of Internal Medicine, University Regensburg, Germany;
and §University of Alabama at Birmingham, USA
Research of the last years has demonstrated clearly the role of
rheumatoid arthritis synovial fibroblasts (RA-SF) in the destruc-
tion of articular cartilage. It has been understood that RA-SF not
only exhibit features of activation and altered apoptosis, but fol-
lowing attachment to cartilage secrete large amounts of matrix
degrading enzymes that mediate the destruction of extracellular
matrix. Given recent advances in the field of gene transfer, we
have been working on specific strategies to interfere with the
expression of disease relevant matrix degrading enzymes using
the complementary approaches of ribozymes and antisense
expression constructs.
Ribozymes are short RNA molecules that have catalytic activity and
are capable of cleaving mRNA thus inhibiting its translation. We
have used retroviral gene transfer of ribozymes against MMP-1 as
well as cathepsins B and L to inhibit the expression of these
enzymes in RA-SF both in vitro and when implanted together with
normal articular cartilage into severe combined immunodeficient
(SCID) mice. As demonstrated in vitro, gene transfer of such
ribozymes results in a sustained, up to 60% decrease of enzyme
production in RA-SF over 60 days. Currently, SCID mouse experi-
ments are underway to study the effect of gene transfer with these
ribozymes on cartilage degradation in vivo.
To evaluate the potential of antisense constructs as an alternative
approach, we have generated antisense constructs against the
novel MT1-MMP and transduced RA-SF using a retroviral system.
First data indicate a high efficacy of MT1-MMP antisense in inhibit-
ing the production of MT1-MMP. However, constantly high levels
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of MT1-MMP antisense RNA are needed for a sustained effect in
RA-SF. The focus of our current efforts is to optimize the construct
both in terms of specificity and its level of expression.
P3
Clinical evaluation of autologous chondrocytes for
joint repair
M Brittberg*, E Sjögren-Jansson†, L Peterson‡, A Lindahl†
*Cartilage research Unit, Göteborg University, Department of
Orthopaedics, Kungsbacka Hospital, Sweden; †Institute of Laboratory
Medicine, Sahlgrenska University Hospital, Sweden; ‡Gothenburg
Medical Center, Göteborg, Sweden
Autologous cultured chondrocyte transplantation was introduced
in Sweden in 1987 for the treatment of full thickness chondral
defects of the knee. The results from the first 219 patients with a
follow up of 2–10 years treated using this technique are reported.
Patients were assessed with three types of endpoints: patient and
physician derived clinical rating scales, arthroscopy assessments
of cartilage fill, integration, and surface hardness and histology of
graft biopsies. There was a high percentage of good to excellent
results (84–90%) in patients with different types of single femoral
condyle lesions, while other types of lesions had a lower degree of
success (mean 74%). Furthermore, the long-term durability of the
grafted area has been evaluated in a group of 61 patients with
femoral condyle and patellar lesions who where followed for a
mean of 7.4 (range 5–11) years and where the durability was cal-
culated as the comparison between the long-term follow up and
clinical status at 2 years post surgery. At 2 years, 50 of 61 patients
treated were classified as satisfactory and at mean 7.4 years follow
up, 51 of 61 were graded satisfactory. Twelve defects tested bio-
mechanically demonstrated stiffness values ³90% of normal in
67% of the patients and 8/12 graft biopsies showed hyaline-like
characteristics. The good clinical long-term outcomes of autolo-
gous chondrocyte transplantation in these studies are encourag-
ing. Future research programs contain a series of randomized
studies on the different clinical repair methods available and more
research on the cell sources, matrices and repair tissue evaluation.
P4
Viral gene transfer for bone healing
AWA Baltzer
Orthopädische Klinik der Heinrich-Heine-Universität Düsseldorf,
Moorenstrasse 5, 40225 Düsseldorf, Germany
Objectives: Local gene transfer to bone and adjacent tissues offers
promise in cases of bone healing disorders such as segmental bone
defects, non-unions, and aseptic loosening of endoprotheses.
Method and results: Studies in which osteoinductive genes have
been administered therapeutically are predominantly segmental
defect models in rabbits and rats. One additional study has been
performed to prevent bone loss in mice.
The administration of different marker genes to segmental defects
induced transient gene expression locally for up to 6 weeks.
b-galactosidase expression was seen after injection of adenoviral
vectors encoding the LacZ gene within the callus tissue, the bony
ends adjacent to the cuts, and the surrounding muscle. After injec-
tion of Ad-luciferase gene expression was also found predomi-
nantly locally, and besides that very low expression in the liver for
up to 5 days, whereas local expression within bone lasted up to 6,
within the surrounding soft tissues up to 3 weeks. No transgene
expression was seen in the contralateral limb, lung, or spleen.
Injection of adenoviral vectors carrying BMP-2 cDNA led to healing
of the segmental defects after 8–12 weeks, the untreated control
defects did not heal. Vectors encoding the transforming growth
factor-b1 gene increased matrix formation within the defects, but
resulted not in complete mineralization of the newly formed callus
as seen after transduction with the BMP-2 cDNA. The results were
judged by radiographic, histologic, histomorphologic, and biome-
chanical criteria.
Conclusion: The data encourage the further development of genetic
approaches to enhancing bone formation in cases of bone disorders.
P5
Osteoprotegerin (OPG) gene therapy in animal
models of osteoarticular disease
B Bolon, C Carter, M Daris, S Morony, G Campagnuolo,
U Feige, J Sheng
Amgen, Thousand Oaks, CA, USA
The soluble decoy receptor osteoprotegerin (OPG) regulates bone
resorption by inhibiting osteoclast formation, function and survival.
We investigated OPG gene therapy as a means of ameliorating
chronic osteoarticular disease using a mouse ovariectomy (OVX)
model of estrogen deficiency-induced osteoporosis (Mol Ther 2001,
3:1–9). Young adult female mice injected once with an adenoviral
(Ad) vector carrying a human fusion protein combining the OPG
ligand-binding and immunoglobulin constant domains (hOPG-Fc)
developed serum OPG levels that exceeded the threshold needed
for efficacy (as assessed by a marked increase in bone density) for
over 12 months. The extent of OPG production and skeletal
enhancement was titer-dependent. Mice subjected to OVX or sham
surgery and then treated with Ad-hOPG-Fc had significantly more
bone volume and fewer osteoclasts in axial and appendicular bones
after 4 weeks. In contrast, animals given OVX and either a control
vector expressing b-galactosidase or vehicle had significantly less
bone than did comparably treated, sham-operated mice. This study
confirms that a single Ad gene transfer can produce persistent high-
level OPG expression and shows that OPG gene therapy may prove
useful in treating osteoporosis. We anticipate that OPG gene
therapy will offer similar promise as a bone-sparing agent in chronic
arthritis since we have shown previously that injected OPG signifi-
cantly inhibits skeletal erosion in the Lewis rat model of mycobacter-
ial-induced adjuvant arthritis (Nature 1999, 402:304–309).
P6
In vivo selection of synovial specific targets using
phage display technology
C Pitzalis
London
Phage display technology has been demonstrated to be a powerful
tool in identifying peptide motifs critical for cell adhesion [1]. We
aim to use this technology to identify novel synovial determinants
using the human synovium/SCID mouse transplantation model.
First, to validate the capacity of the library to identify specific
ligands, we tested in vitro its ability to recognize the integrin avb3
which displays a specific RGD peptide binding motif [2]. Three
rounds of selection were performed on a BSA blocked, avb3
(0.5mg/well) coated microtiter plate. Bound phages were recov-
ered by acid elution and amplified in E coli. As expected, a striking
enrichment in the third round of selection was obtained for RGD
containing clones. In addition, novel flanking sequences were iden-
tified in six of the clones.Having validated the library, to select in vivo synovial determinants,
three rounds of enrichment were performed using 6-week-old
SCID mice transplanted with human synovium [3]. Four weeks
post-transplantation, 109TU/ml phages were injected intravenously
into the tail vein. The phages were allowed to recirculate for 5 min
and animal sacrificed following perfusion through the heart to
remove unbound phages. In each round a significant enrichment
for synovial tissue was obtained. We are currently engaged in the
characterization of these novel determinants.
References
1. O’Neil KT, et al: Modern methods in extracellular matrix research.
1999: 370–386.
2. Ruoslahti E. Annu Rev Cell Dev Biol 1996, 12:697–715.
3. Wahid, et al: Clin Exp Immunol 2000, 122:133–142.
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Evidence for re-differentiation of human
chondrocytes seeded on a hyaluronan derivative
scaffold
B Grigolo*, G Lisignoli*, A Piacentini*, M Fiorini*, L Roseti†, 
EO Major†, M Duca‡, A Pavesio‡, A Facchini*
Laboratorio di Immunologia e Genetica, Istituti Ortopedici Rizzoli,
Bologna, Italy; Laboratory of Molecular Medicine and Neuroscience,
National Institute of Neurological Disorders and Stroke, NIH,
Bethesda, MD, USA; Fidia Advanced Biopolymers, Abano Terme, Italy
Association of biomaterials with autologous chondrocytes promises
to provide a new generation of implantable devices for cartilage
repair. HYAFF®-11 is a recently developed hyaluronic-acid based
biodegradable polymer, that has been shown to provide successful
cell scaffold for tissue-engineered repair. The aim of this study was
to estimate the capacity of HYAFF®-11 to support the growth of
human chondrocytes and their original phenotype. To this end,
human chondrocytes (106cells/cm2) were seeded on HYAFF®-11
and their proliferation and differentiation were assessed at different
time points. Gene expression for collagen I, II and aggrecan was
revealed by RT-PCR evaluating the presence of the specific
mRNAs, while histochemical analyses for these proteins were per-
formed by the use of specific monoclonal antibodies. Our data indi-
cate that human chondrocytes seeded on HYAFF®-11 after
expansion  in vitro, re-express and produce collagen type II and
aggrecan and downregulate the production of collagen type I.
HYAFF®-11 was also utilized to stabilize the phenotype of an
immortalized human chondrocyte line obtained by liposome-medi-
ated transfection with the p16HHMo plasmid encoding two
HPV16 early function genes.
These results prove that normal and transfected human chondro-
cytes can grow and differentiate on a hyaluronan-based scaffold
(HYAFF®-11) which can be used as a delivery vehicle for the repair
of articular cartilage defects.
P8
AKT regulates TNF-a a-mediated apoptosis of
rheumatoid arthritis synovial fibroblasts
JD Mountz, H-G Zhang, Y Wang, JF Xie, X Liang, H-C Hsu, DT Curiel
The University of Alabama at Birmingham and Birmingham VAMC,
Birmingham, AL 35294, USA
Objective: To determine whether TNF-a driven proliferation of
rheumatoid synovial fibroblasts is associated with upregulation of
the serine/threonine kinase B (PKB)/AKT activity and RA synovial
fibroblast survival.
Method: Staining of phosphorylated AKT was done using
antiphosphorylated Thr308-AKT antibody. Phosphorylated AKT
was analyzed by Western blot, and AKT activity was analyzed
using a kinase assay. The cytotoxicity of TNF-a treatment or
TNF-a plus AKT activity inhibitor wortmannin, TNF-a plus domi-
nant mutant (AdAkt-DN) or AdPTEN was analyzed using ATPLite
assay.
Results: The levels of phosphorylated-Akt are higher in RASF than
in OASF, as demonstrated by immunohistochemical staining,
immunoblot analysis and an Akt kinase assay. The levels of phos-
phorylated Akt and Akt kinase activity were increased by stimula-
tion of primary RASF with TNF-a (10ng/ml). Treatment of RASF
with the PI 3-kinase inhibitor, wortmannin (50nM), plus TNF-a
resulted in apoptosis of 75±8% of RASF within 24h. This
proapoptosis effect was specific for Akt, as equivalent levels of
apoptosis were observed upon TNF-a treatment of RASF trans-
fected with adenovirus expressing a dominant negative-Akt
(AdAkt-DN) and with an adenovirus expressing PTEN (AdPTEN),
which opposes the action of Akt.
Conclusion: These results indicate that phosphorylated Akt acts
as a survival signal in RASF and contributes to the stimulatory
effect of TNF-a on these cells by inhibiting the apoptosis response.
This effect was not observed in OSAF, and may reflect the patho-
physiologic changes associated with the proliferating synovium in
rheumatoid arthritis.
P9
AAV mediated delivery of IL-4 prevents collagen-
induced arthritis
N Bessis, M-C Boissier
UPRES EA-2361, Departement de Rhumatologie, UFR Léonard de
Vinci, Université Paris 13, Bobigny, France
Immunomodulation of autoimmune inflammatory diseases like
rheumatoid arthritis can be achieved by anti-inflammatory T2
cytokines such as interleukin (IL)-4 administered by gene therapy.
Engineered cells secreting cytokines was the first demonstrated
efficient gene therapy in animals models of arthritis. Adeno-associ-
ated virus (AAV) are new gene therapy vectors exhibiting a
number of advantages over the others vectors. AAV is a small
DNA virus of the Parvoviridae family. In human populations, the
overwhelming majority of individuals have been exposed to the
AAV, which doesn’t seem to have known pathological effects. In
addition to being safe, AAV vectors can infect a broad spectrum
of host cells, at any phase of their division cycle. Furthermore,
recombinant AAV vectors contain no viral genes but only the
transgene flanked by two inverting terminal repeats (ITRs), which
could package moderately sized transgenes, such as those
encoding for cytokines.
We recently investigated the efficiency of adeno-associated virus
(AAV) vectors in collagen-induced arthritis (CIA). After injection
of AAV-lacZ in the tarsus area of mice, the expression of the
transgene was localized in the deep muscle cells near the bone.
LacZ expression was found in liver, heart and lung after intramus-
cular injection of AAV-LacZ, showing a spread of the vector over
the body. Anti-AAV neutralizing antibodies were detected in the
serum after intramuscular injection of AAV-LacZ, but they didn’t
alter the transgene expression after re-administration of AAV-
LacZ. Long-term IL-4 expression persisted 129 days after intra-
muscular injection of 3.7×1010 or 11.2×1010 AAV-IL-4 pp
(average 7.7 or 17.5 pgIL-4/mg proteins, respectively). More
importantly, the treatment of CIA with AAV-IL-4 vector in mice
produced a therapeutic benefit, since we show a diminished
prevalence of the disease, a significant reduction in paw swelling,
Available onlinehttp://arthritis-research.com/supplements/3/S1attenuated histological synovitis and a 10 day delayed onset of
arthritis. These data show evidence that AAV vector-mediated
gene therapy using a T2 cytokine is efficient in an animal model
of rheumatoid arthritis.
Reference
1. Cottard V, Mulleman D, Bouillé P, Mezzina M, Boissier M-C, Bessis
N: Adeno-associated virus delivery of IL-4 prevents collagen-
induced arthritis. Gene Ther 2000, 7:1930–1939.
P10
IKKb b and p53 as therapeutic targets for arthritis
PP Tak
Division of Clinical Immunology and Rheumatology, AMC,
Amsterdam, The Netherlands; Division of Rheumatology, UCSD,
La Jolla, CA, USA
The disparity between the proportion of cells with DNA strand
breaks and the low number of apoptotic cells in rheumatoid syn-
ovial tissue suggests impaired apoptosis. Therefore, therapeutic
strategies aimed at induction of apoptosis in rheumatoid synovial
tissue may be attractive. Adjuvant arthritis (AA) in rats is among the
most commonly used model for rheumatoid arthritis (RA). To char-
acterize the extent to which apoptosis occurs in the natural course
of the disease, we evaluated the number of apoptotic cells and the
expression of p53 in various phases of AA. We found that signifi-
cant apoptosis only occurs late in AA and this is concordant with
marked p53 overexpression, making it a useful model for testing
proapoptotic therapies. Intra-articular adenoviral gene transfer of
wild-type p53 resulted in an incremental increase in p53 expres-
sion in the injected joints, but this therapy did not have a beneficial
clinical effect, since there was already dramatic p53 overexpres-
sion in the later stages of AA.
NF-kB activation is another factor involved in the persistent acti-
vation of synovial cells and impaired apoptosis. IkB kinase b
(IKKb) is a key regulator of NF-kB. We observed the develop-
ment of arthritis after intra-articular adenoviral gene transfer of
IKKb-wt into the joints of normal rats. Increased IKK activity was
detectable in the Ad.IKKb-wt injected ankle joints, coincident
with enhanced NF-kB binding activity. Conversely, intra-articular
gene transfer of Ad.IKKb-dn significantly ameliorated the severity
of adjuvant arthritis in Lewis rats. This effect was accompanied
by a significant decrease in levels of NF-kB binding activity. Tar-
geting IKK activity may represent a valid new strategy for the
treatment of RA.
P11
Engineering T cells and molecules for targeting
joints and inflammation
Y Chernajovsky, A Annenkov, H Dreja, G Adams
Bone and Joint Research Unit, St Bartholomew’s and Royal London
School of Medicine, Queen Mary, University of London, Charterhouse
Square, London EC1M 6BQ, UK
Objective: Rheumatoid arthritis (RA) is a chronic autoimmune
inflammatory disease characterised by cartilage and bone
erosion. In order to target the joint and the inflammation process
specifically, avoiding systemic secondary effects of biological
compounds, we have: engineered T cells to recognise collagen
type II (CII), a main constituent of cartilage, with a chimeric
receptor composed of a scFv extracellular domain which binds to
CII and an intracellular domain which signals inducing cytokine
production and T cell proliferation; and modified cytokines with a
biodegradable ‘shell’ that is removed in sites of inflammation by
MMP activity.
Results: Primary T cells grafted with the chimeric scFv receptor
with a z chain intracellular domain via retroviral transduction, form
homodimeric receptors in the cell surface recognising CII in vitro
both in solution and attached to plastic and respond producing
IL-2 and IFN-g. KLH-specific T cells produce also IL-4 when chal-
lenged with KLH but upon grafting with the chimeric receptor lose
the ability to produce this Th2 cytokine. This is in agreement with
preliminary findings that engineered T cells are arthritogenic in vivo
following CII challenge.
We have produced a fusion protein between a cytokine and a
protective protein subunit linked via an MMP cleavage site. We
show in vitro that the engineered fusion protein is inactive (inca-
pable of binding to its cellular receptors) unless cleaved by
MMP1, MMP3 or by synovial fluid of RA patients. Intramuscular
injection of the plasmid expressing a ‘mutated’ active versus the
‘inactive’ form of the protein showed that the latter was more
effective as expected in the treatment of collagen-induced arthri-
tis in DBA/1 mice.
Conclusion: Engineering cells and molecules to achieve site-
specific activation has advantages for gene therapy of RA.
P12
Elimination of rheumatoid synovium in situ by Fas
ligand ‘gene scalpel™’
H Zhang*, G Gao†, G Clayburne‡, JM Wilson†, HR Schumacher*‡
*Division of Rheumatology, †Institute for Human Gene Therapy,
University of Pennsylvania, ‡VA Medical Center, PA 19104, USA
Introduction: Surgical synovectomy to remove the inflammatory
synovium, can temporarily ameliorate rheumatoid inflammation
and delay the progress of joint destruction. An efficient medically
induced programmed cell death (apoptosis) in the RA synovium
might play a similar role as synovectomy. Gene transfer of FasL
has increased the frequency of apoptotic cells in collagen
induced mouse arthritis synovium. In this study, we investigated
whether a repeated FasL gene transfer could function as a mole-
cular synovectomy to remove human inflammatory synovial tissue
in situ.
Method: RA synovium and cartilage from joint replacement surg-
eries of 5 patients were cut into small pieces at about
2×3×3mm 3/piece and then was grafted subcutaneously into male
C.B-17 SCID mice aged 6–7 weeks at 0.2g tissue per mouse.
Injections of a recombinant FasL adenovirus into the grafted syn-
ovial tissue at the dosage of 1011 particles per mouse were per-
formed twice/month. The control groups were treated with
recombinant LacZ adenovirus at the same dosage and time points
as Ad-FasL administration.
Results: Compared to the control Ad-LacZ injected RA syn-
ovium, the Ad-FasL injected RA-synovium was dramatically
reduced in size and weight. After 8 weeks the weights of
grafted RA synovium were 0.039±0.024g in the Ad-FasL
treated group and 0.152±0.021g in the Ad-LacZ treated
group (P<0.01). Both synoviocytes and mononuclear cells
were greatly decreased after the 2 months treatment with
Ad-FasL.
Conclusion: Our in vivo investigation of gene transfer to human
synovium in SCID mice suggests that arresting inflammatory syn-
ovium at an early stage of RA by intra-articular gene transfer of an
apoptosis inducer, such as FasL, might be possible.
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Double and triple gene transfer in arthritis
U Müller-Ladner*, E Neumann*, M Fleck*, T Pap†, RE Gay†,
PD Robbins‡, JD Mountz§, CH Evans‡, J Schölmerich*, S Gay†
*Department of Internal Medicine I, University of Regensburg,
Germany; †Ctr Exp Rheum, Department of Rheumatology, USZ,
Switzerland; ‡Harvard University, Boston, USA; §Department of
Rheumatology, UAB, Birmingham, USA
Objective: As single gene transfer using virus-encoded inhibitory
molecules such as IL-1Ra, IL-10 and sTNFaRP55 resulted in dif-
ferent benefical effects on cartilage destruction in the SCID mouse
model for RA, we examined the outcome of double and triple gene
transfer in this model and analyzed the molecular effects induced
by this approach.
Method: RA synovial fibroblasts were transduced using adenoviral
sTNFaRp55 and retroviral IL10- or IL1Ra-encoding MFG vectors.
Thereafter, transduced cells were mixed in various double and
triple combinations and coimplanted with human cartilage for 60
days in SCID mice. Protein expression of the transduced genes
was monitored throughout the experiment. RNA of transduced
cells was isolated and expression of proto-oncogenes and signal-
ing molecules before and after gene transfer was analyzed using
RNA arbitrarily primed PCR (RAP-PCR), cDNA expression array
and real-time PCR.
Results: When compared to single gene transfer, combination of
IL-1Ra and IL-10 overexpression showed the strongest additive
effect resulting in both decrease of perichondrocytic cartilage
degradation and reduction of invasion of fibroblasts into the carti-
lage. IL-1Ra and IL-10 double gene transfer resulted also in dis-
tinct alterations of gene expression of molecules involved in cell
activation and metabolism. In contrast, double gene transfer with
TNFaRp55 did not improve the beneficial effects of IL-10 or those
of IL-1Ra. Moreover, triple gene transfer using these three
inhibitory molecules partly antagonized the benficial effects
observed in double gene transfer both in the SCID mouse as well
as on the molecular level.
Conclusion: In summary, double gene transfer of inhibitory mole-
cules results in additive effects on cartilage protection and expres-
sion of genes involved in cartilage degradation in RA, whereas a
less beneficial outcome may result following gene transfer of addi-
tional genes.
P14
Bone stem cell mediated gene therapy and tissue
engineering
D Gazit
Hebrew University Hadassah Medical and Gene Therapy Center,
Jerusalem, Israel
Mesenchymal stem cells (MSCs) are key regulators in senile
osteoporosis and they are suitable candidates for stem cell medi-
ated gene therapy in local and systemic bone disorders and tissue
engineering. We hypothesized that genetically engineered MSCs,
expressing rhBMP2, can be utilized for gene therapy targeted to
bone regeneration and bone/cartilage tissue engineering. We
conditionally expressed rhBMP2 in mouse and human mesenchy-
mal stem cells. RhBMP2 expressing clones (tet-off), AAV-BMP2
and adeno-BMP2 spontaneously differentiated into osteogenic
cells  in vitro and in vivo. Clones were transplanted and tracked in
vivo in radial segmental defects (regenerating site) and in ectopic
muscular and subcutaneous sites (nonregenerating sites). In vitro
and in vivo analysis revealed rhBMP2 expression and function,
confirmed by PCR, RT-PCR, ELISA, Westerns, immunohisto-
chemistry, and bioassays. Secretion of rhBMP2 in vitro was con-
trolled by tetracycline (in the designated clone) and resulted in
secretion of 1231ng/24h/106 cells. Quantitative Micro QCT
three-dimensional reconstruction revealed complete bone regen-
eration regulated by tetracycline in vivo, indicating the potential of
this platform for bone and cartilage tissue engineering. Moreover,
transplants of rhBMP2 expressing clones (tet-off) exhibited more
than a 10-fold increase in angiogenesis, a crucial element in
tissue engineering. We are currently characterizing a novel tissue
engineering platform composed of engineered cells and scaffolds,
creating 3D bone tissue in bioreactors, clearly indicating that our
regulated clones and polymeric scaffolds can be utilized for tissue
engineering. Our study should lead to the creation of gene thera-
pies for systemic and local bone diseases in humans and bone/
cartilage tissue engineering.
P15
Enhanced chondrocyte apoptosis leads to
abnormal cartilage in rats and cats with
glycosaminoglycan storage diseases
CM Simonaro*, ME Haskins‡, EH Schuchman*†
*Department of Human Genetics and †Institute for Gene Therapy
and Molecular Medicine, Mount Sinai School of Medicine, New
York, NY 10029, USA; ‡Department of Pathobiology, University of
Pennsylvania School of Veterinary Medicine, Philadelphia, PA
19104, USA
The mucopolysaccharidoses (MPS) are a family of glycosamino-
glycan (GAG) storage diseases caused by the deficient activities
of specific lysosomal enzymes. A major feature of the MPS disor-
ders is abnormal cartilage and bone development leading to
short stature, dysostosis multiplex, and degenerative joint
disease. Ultrastructurally, the cytoplasm of affected MPS chon-
drocytes is filled with membrane bound vacuoles containing
undegraded GAGs. Clusters of hypertrophic chondrocytes form
in these disorders, leading to the disruption of the normal carti-
lage organization. To further investigate the cellular pathology of
the MPS disorders, primary cultured chondrocytes and articular
cartilage were examined from cats and rats with MPS type VI
(Maroteaux–Lamy disease). Markedly increased numbers of
apoptotic chondrocytes were identified by TUNEL staining and
immunohistochemically with anti-poly (ADP-ribose) polymerase
antibodies in the MPS animals as compared to age-matched con-
trols. The prevalence of apoptotic cells was correlated with
increased levels of nitrite and tumor necrosis factor-a. Marked
proteoglycan depletion also was observed in the MPS epiphyses
by Safranin-O staining, and the presence of excess collagen type
II was detected by immunostaining. A model of MPS endo-
chondryl bone pathology is proposed in which an inflammatory
response to mechanical trauma is caused by the deformed and
irregular subchondral bone contours, leading to increased nitric
oxide (NO) production in response to TNF-a, thereby inducing
chondrocyte cell death. Novel treatment strategies for these dis-
orders might, therefore, be considered to prevent inflammation or
inhibit NO production as an alternative to providing the missing
enzymatic activities.
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Transfer of protease inhibitors to inhibit cartilage
destruction
WH van der Laan*†, T Pap‡, PHA Quax†, JM TeKoppele†,
FC Breedveld*, S Gay‡, RE Gay‡, JH Verheijen†, TWJ Huizinga*
*Department of Rheumatology, Leiden University Medical Center,
Leiden, The Netherlands; †Department of Vascular and Connective
Tissue Research, TNO Prevention and Health, Leiden, The
Netherlands; ‡Center for Experimental Rheumatology,
UniversitätsSpital Zürich, Switzerland
Objective: Proteases such as serine proteases and matrix metallo-
proteases (MMPs) are involved in cartilage destruction in rheuma-
toid arthritis. The effects of gene transfer of plasmin inhibitors and
tissue inhibitors of metalloproteinases (TIMPs) on cartilage degra-
dation and invasion by rheumatoid synovial fibroblasts were investi-
gated.
Method: Replication defective adenoviral vectors were used for
transduction. Genes encoding the following inhibitors were used:
the plasmin inhibitor, bovine pancreatic trypsin inhibitor (BPTI); a
cell surface-targeted plasmin inhibitor, ATF.BPTI, a hybrid protein
of BPTI and a ligand of the cell surface uPA-receptor, ATF;
TIMP-1; and TIMP-3. Cartilage degradation was investigated in an
in vitro model using a radiolabeled cartilage-like matrix. The inva-
sive behavior of rheumatoid synovial fibroblasts was studied in vitro
in a Transwell model and in vivo in the SCID mouse co-implanta-
tion model.
Results and conclusion: Cartilage degradation was significantly
reduced by gene transfer of BPTI and ATF.BPTI. The effect of
ATF.BPTI was significantly stronger than that of BPTI suggesting
that targeting protease inhibition to the cell surface improves the
inhibitory effect. Gene transfer of ATF.BPTI, TIMP-1 and TIMP-3
significantly inhibited cartilage invasion. These results indicate that
cartilage degradation and invasion can be inhibited by gene trans-
fer of inhibitors of plasmin and MMPs. Inhibition of proteases at the
site of joint destruction through gene transfer may provide a novel
therapeutic strategy to limit the progression of joint destruction in
rheumatoid arthritis.
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Local interleukin-12 gene transfer promotes
conversion of an acute to a chronic destructive
murine streptococcal cell wall arthritis
LAB Joosten, M Heuvelmans-Jacobs, E Lubberts, FAJ van de
Loo, MMA Helsen, WB van den Berg
Rheumatology Research Laboratory, UMC St-Radboud, Nijmegen,
The Netherlands
Objective: Interleukin-12 is a pleiotropic cytokine that is produced
by mononuclear phagocytes, dendritic cells and B cells, and it
promotes the growth of activated T cells and NK cells. IL-12
selectively generates the development of naïve T cells into Th1
cells. IL-12 is effectively produced by macrophages upon stimula-
tion with LPS, several bacteria and intracellular parasites. The
goal of the present was to determine whether local overexpres-
sion of IL-12 converts an acute joint inflammation to a chronic
destructive arthritis.
Method: SCW arthritis was induced in IL-12 deficient mice to
examine the IL-12 dependency. C57Black/6 mice were injected
intra-articularly with either saline, 107 pfu control vector
(Ad5del70-3) or IL-12 vector (AdmIL-12.1) into the right knee
joint one day before the mice were injected intra-articularly with
25mg SCW fragments. Thereafter, joint swelling, chondrocyte
proteoglycan (PG) synthesis and joint destruction were exam-
ined. In addition MMP activity was visualized by VDIPEN staining.
Arthritis was exacerbated by intravenous injection of 100mg
SCW fragments.
Results: IL-12-deficient mice showed reduced joint swelling after
injection of SCW fragments. High levels of IL-12 (up to 20ng/ml at
day 1) could be detected after application of AdIL-12 vector. After
14 days still expression of IL-12 (1ng/ml) was found locally without
significant inflammation. Local expression of IL-12 reveals to aggra-
vate SCW arthritis as determined by enhanced joint swelling and
inhibition of chondrocyte PG synthesis. Histology taken at day 21
showed a chronic inflammatory process in the AdIL-12 transfected
knee joints. Enhanced cartilage PG depletion and cartilage
destruction was noted in the AdIL-12 group, whereas this was not
seen in the Ad5del70-5 group. In line with these findings, metallo-
proteinase activity, visualized by VDIPEN expression in the carti-
lage layers, was only found in AdIL-12 group. In addition, systemic
challenge of arthritis was only possible in the AdmIL-12 group, indi-
cating a T cell mediated process.
Conclusion: These results indicate that local expression of IL-12
can promote conversion of an acute to a chronic destructive
arthritic process.
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inflammation-inducible intra-articular production
of human IL-1 receptor antagonist results in a
more efficient inhibition of collagen-induced
arthritis than does constitutive expression of the
same transgene
AC Bakker*, FAJ van de Loo*, MB Bennink*, LAB Joosten*,
AW Varley†, RS Munford†, WB van den Berg*
*Department of Rheumatology, UMC St Radboud, 6525 GA
Nijmegen, PO box 9101, The Netherlands; †Molecular Host Defense
Laboratory, Department of Internal Medicine, UT Southwestern
Medical Center, Dallas, USA
Objective: To achieve disease-inducible expression of recombi-
nant anti-inflammatory proteins in order to allow autoregulation of
drug dose by natural homeostatic mechanisms.
Method: We compared a disease-inducible, two component
expression system (C3-Tat/HIV) with the constitutive
cytomegalovirus (ie CMV) promoter in the polyarticular collagen-
induced arthritis (CIA) model. DBA/I mice were immunized with
bovine type II collagen and boostered on day 22. On day 22,
mice without any clinical signs of arthritis were selected and
10e7 PFU of the adenoviral vectors (Ad5.CMV-Luc,
Ad5.CMV-IL-1Ra, or Ad5.C3-Tat/HIV-IL-1Ra) that contained
either luciferase (Luc) or the human IL-1Ra gene under control
of one of the two promoters were used to transfect the synovial
lining of both knees. The injected knee joints and ipsilateral
paws were then scored for signs of arthritis and at the end his-
tology was taken.
Results: Inducible promoter-driven IL-1Ra expression resulted in
significantly improved inhibition of CIA than did CMV-driven IL-1Ra
production. Moreover, overexpression of IL-1Ra in the knee joints
also prevented CIA in the ipsilateral paws.
Conclusion: Our data demonstrate the feasibility of an inducible
expression system for producing a transgene for treatment of
arthritis; and show that this system is more effective than strong,
constitutive transgene expression for preventing collagen-induced
arthritis in mice.
Acknowledgement: This study was financially supported by the
Dutch Arthritis Association (941) and the Dutch Organization for
Scientific Research (902-27-218).
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Using a tropism-modified adenoviral vector for
the intra-articular production of IL-1 receptor
antagonist results in a more efficient inhibition of
collagen-induced arthritis than does a
conventional Ad5 vector
AC Bakker*, FAJ van de Loo*, OJ Arntz*, LAB Joosten*,
I Dmitriev†, V Krasnykh†, DT Curiel†, WB van den Berg*
*Department of Rheumatology, UMC St Radboud, 6525 GA
Nijmegen, PO box 9101, The Netherlands; †UAB, Birmingham 
AL 35294-3300, USA
Objective: Introducing an Arg-Gly-Asp (RGD) motif in the HI loop
of the fiber knob results in the ability of the adenovirus to utilize the
avb3 and avb5 integrins instead of the coxsackie-adenovirus
receptor for cell recognition. In this study we compared the trans-
fection efficiency and the effect of intra-articular IL-1Ra gene deliv-
ery on collagen-induced arthritis (CIA) using RGD modified and
conventional Ad5 vectors.
Method: DBA/1 mice were immunized with collagen type II, and
boostered 22 days later. Four days after the booster, 107 pfu of the
Ad5Luc, Ad5Luc.RGD, Ad5mIL-1Ra, or Ad5mIL-1Ra.RGD were
injected bilaterally into the knee joint cavity. The clinical score
(scale 0–2) of the ipsilateral paws was taken during the course of
arthritis, and the knees were scored (scale of 0–3) at the end of
the experiment.
Results: 24-h after the intra-articular injection into normal knee joints
the luciferase (Luc) production was around 22 times higher using the
Ad5Luc.RGD as compared to a conventional Ad5Luc vector. Intra-
articular injection of 107pfu adenoviral vectors at day 26 of immuniza-
tion resulted in a significant inhibition of CIA in the Ad5mIL-1Ra.RGD
group (clinical score of the knee at day 38 was 0.82±0.24) as com-
pared to the other groups (clinical scores were 1.57±0.24 for the
Ad5mIL-1Ra group and 1.86±0.21 for the Ad5Luc.RGD group).
Conclusion: Our data demonstrate that the RGD modification of
adenoviruses improved the synovial transfection efficiency; and that
the Ad5IL-1Ra.RGD vector was more efficacious in the treatment of
arthritis than the conventional vector with the same transgene.
Acknowledgement: This study was financially supported by the
Dutch Arthritis Association (941) and the Dutch Organization for
Scientific Research (902-27-218).
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Local IL-17 gene therapy accelerates collagen
arthritis with severe bone erosion and rank ligand
and rank expression in synovial infiltrate and at
bone erosion sites
E Lubberts*, LAB Joosten*, P Schwarzenberger†, B Oppers*,
L van de Bersselaar*, JK Kolls†, WB van den Berg*
*UMC St Radboud, Rheumatology Research Laboratory, Nijmegen,
The Netherlands; †Gene Therapy Program, Louisiana State University,
New Orleans, LA, USA
Objective: To examine the effects of local IL-17 application in the
knee joint of type II collagen immunized mice on the induction of
bone erosion.
Method: Collagen-induced arthritis (CIA) was induced in male
DBA-1 mice by immunizing intradermally at the base of the tail with
suboptimal dose of bovine type II collagen. On day 21, mice were
given an intraperitoneal booster injection of the same dose of type II
collagen dissolved in PBS. Just before expected onset, mice were
intra-articularly injected into the right knee joint with 107pfu of either
an IL-17 expressing (AdIL-17) or control (AdControl) recombinant
human type 5 adenovirus vector. Five days after the intra-articular
injection of the viral vector arthritis was monitored visually and joint
pathology was examined by histology. Formation of osteoclast-like
cells was determined by tartrate-resistant acid phosphatase (TRAP)
staining. In addition, RANKL and RANK protein expression was
evaluated by specific immunohistochemistry.
Results: Local IL-17 over-expression in the knee joint of type II col-
lagen immunized mice promotes synovial inflammation. Five days
after viral injection of AdIL-17 histologic analysis showed aggrava-
tion of bone erosion in the patella and femur/tibia region compared
with the control vector group. Induction of bone destruction by
IL-17 was accompanied with marked tartrate-resistant acid phos-
phatase (TRAP) activity in the bone marrow and at bone erosion
sites, indicating that IL-17 accelerates the formation of osteoclast-
like cells. Interestingly, local IL-17 promotes local protein expres-
sion of RANKL and its receptor RANK in the synovial infiltrate and
at bone erosion sites compared with the control vector group.
Conclusion: These data show that local IL-17 gene therapy during
onset of collagen arthritis promotes osteoclastic bone erosion
accompanied with accelerated expression of local RANKL and its
receptor RANK. These findings suggest IL-17 to be a potent stimu-
lator of osteoclastogenesis during arthritis.
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Update on the contralateral effect in rabbit and
mouse models
PD Robbins*, ER Lechman*, S-H Kim*, A Gambotto*, J Whalen*,
SC Ghivizanni†, CH Evans†, Z Mi*, TJ Oligino*
*University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA;
†Center for Molecular Orthopaedics, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USA
While screening several anti-inflammatory gene products for effi-
cacy in rabbit and murine models of RA by intra-articular adenoviral
injection, a therapeutic effect was observed in both the treated and
untreated contralateral joints. This contralateral effect was
observed following adenoviral gene transfer of IL-1Ra, sIL-1 recep-
tor, sTNF-receptor, vIL-10 and IL-4. Several different experiments
suggested that the therapeutic effect may be due, in part, to the
migration of a population of virally transduced antigen presenting
cells (APC) from the treated joint to the regional lymph nodes and
the untreated arthritic joints. Consistent with this model, we have
demonstrated that direct intravenous injection of genetically modi-
fied DC expressing IL-4, FasL, IL-1Ra or CTLA4-Ig resulted in sup-
pression or elimination of established collagen induced arthritis.
However, intra-articular ex vivo delivery of retrovirus transduced
syngeneic synoviocytes expressing anti-inflammatory factors con-
ferred a similar therapeutic effect in treated as well as untreated
contralateral joints. The results from our ex vivo and in vivo studies
suggested that trafficking of vector-modified inflammatory cells
may not be the main mechanism responsible for the observed con-
tralateral effect. We now propose that local, intra-articular expres-
sion of anti-inflammatory factors may be able to modify the function
of APCs that are then able to modulate the immune response in
the contralateral joint. In support of this model, injection of APC
treated with either recombinant IL-10 protein or infected with
Ad.vIL-10 were able to block the DTH response in both the treated
and untreated paws. We also have demonstrated that exosomes
derived from Ad.vIL-10 infected APC were able to reduce the DTH
response in both the treated and untreated paws. Taken together
these results suggest that modified APC as well as APC derived-
exosomes can confer a novel protective, anti-inflammatory effect in
treated and untreated contralateral joints.
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Viral, nonviral and peptide-mediated intra-
articular transfer of genes and proteins
PD Robbins*, Z Mi*, X Lu*, J Mai*, SC Ghivizanni†, CH Evans†,
TJ Oligino*
*University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA;
†Center for Molecular Orthopaedics, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USA
We have been examining the ability of different vectors to transfer
therapeutic genes directly to joints following intra-articular injec-
tion. To date, we have examined the efficiency of intra-articular
gene transfer to the rabbit knee mediated by adenoviral, adeno-
associated virus (AAV), retrovirus and herpes simplex virus vectors
as well as by over 100 different nonviral formulations. Moreover,
we have examined the ability to repeat dose with the different types
of viral vectors. A summary of our experiments to identify a clinically
useful vector for intra-articular gene transfer will be presented. In
an attempt to improve intra-articular gene transfer, we also have
screened an M13 peptide phage display library for peptides able
to facilitate internalization into synovial cells. We have identified a
class of cationic peptides (PTD), similar to the cationic protein
transduction domains found in Antennapedia (Antp) and HIV TAT
peptide, as well as a class of more neutral and hydrophobic pep-
tides (HAP). To determine the ability of the PTD and HAP peptides
to facilitate internalization, the peptides were biotinylated and
coupled to avidin-b-gal or streptavidin-Cy3. Although internalization
mediated by the HAP peptides in culture and in vivo was not as
efficient as the cationic peptides, they appeared to be more cell
type specific. Several of the HAP and PTD peptides were fused to
an antimicrobial peptide, KLAK, generating novel apoptotic pep-
tides. These fusion peptides were able to impair rabbit and human
synovial cell viability through disruption of mitochondria and induc-
tion of apoptosis. Intra-articular injection of these apoptotic pep-
tides into arthritic rabbit joints resulted in extensive synovial cell
apoptosis as well as reduction in leukocytic infiltration. An update
of our progress using the different internalizing peptides for deliv-
ery of therapeutic proteins and genes will be presented.
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In vitro and in vivo differentiation of mesenchymal
stem cells into chondrocytes
D Noël*, F Apparailly*, V Millet*, J Sany†, C Jorgensen*†
*INSERM U475, 99, rue Puech Villa, 34197 Montpellier cedex 5,
France; †CHU Lapeyronie, Service d’Immunorhumatologie, avenue du
Doyen Gaston Giraud, 34295 Montpellier cedex, France
Mesenchymal stem cells are multipotent cells that have the poten-
tial to differentiate toward multiple lineages, such as adipocytes,
myocytes, osteocytes and chondrocytes. Both primary stem cells
originating from bone marrow and immortalised cell lines retain
their differentiation capacities when cultured in vitro under specific
conditions. Growth factors of the TFG-b superfamily have been
shown to have the properties of inducing in vitro osteogenic and
chondrogenic differentiation. The purpose of this work was to
compare the potential of different growth factors (BMP-2, CDMP-1
and CDMP-2) and the Sox-9 chondrocyte-specific transcription
factor to induce the chondrogenic differentiation of mesenchymal
stem cells both in vitro and in vivo.
To this aim, we first derived mesenchymal stem cells (from the
murine C3H10T1/2 line) constitutively expressing either one of the
growth or transcription factor. The chondrogenic potential of these
factors was then assessed in vitro using the micropellet culture
system both by RT-PCR and immunohistochemistry. Those cells
were then embedded in a type I collagen matrix and subcuta-
neously implanted in SCID mice. The matrices were retrieved after
20 days and processed for routine histology and immunohisto-
chemistry analysis. Parallely, BMP-2-expressing stem cells were
injected into the intra-articular space of SCID mouse knee joints to
determine their capacities of in situ differentiation and cartilaginous
matrix formation.
Intra-articular injection of mesenchymal stem cells engineered to
express BMP-2 gave rise to the formation of bone in the knee joint
and at extra-articular sites, particularly in muscle. The need for dif-
ferentiation factors, specific for cartilage, is underlined.
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Inhibition of collagen-induced arthritis in mice by
inducible AAV-mediated transfer of viral IL-10
gene
F Apparailly, V Millet, C Jacquet, J Sany, C Noël, C Jorgensen
INSERM U475, CHU Lapeyronie, Montpellier, France
Objective: The purpose of this study is to assess the therapeutic
efficiency of vIL-10 gene transfer mediated by a tetracycline-
inducible AAV vector in mice model of arthritis.
Method: The AAV-tetON-vIL10 vector (1.5×109pi) was injected
intramuscularly 3 weeks before immunization with bovine type II
collagen. DBA1 mice with collagen-induced arthritis then received
dox diet (200mg/kg) from days 21–42 of immunization. Severity of
arthritis was determined by measuring paw swelling, evaluating
X-ray and histological paw features. Expression of vIL-10 was mea-
sured by RT-PCR and ELISA in injected muscle.
Results: The incidence and severity of arthritis was significantly
reduced at macroscopic, radiologic and histologic levels in the group
of animals treated with AAV-TetON-vIL10 vector plus doxycycline,
compared with vector alone or control groups (AAV-GFP + doxycy-
cline and doxycycline alone). Only 30% of mice developed arthritis
against 89% in controls. Mice from the control groups showed earlier
onset of arthritis, with clinical signs of the disease starting on day
32.63±4.07, compared with 36.67±3.51 in the AAV-TetON-vIL10
injected group treated with doxycycline (P=0.033). The benefit was
not only observed at the inflammatory level, but also on cartilage and
bone erosion (P<0.01). Gene transfer led to detectable levels of
vIL-10 transcript and protein in the AAV-tetON-vIL10 injected
muscles, inducible by doxycycline. A basal transcription of vIL-10 was
observed, significantly induced by doxycycline (×2.7, P=0.0094),
leading to a higher secretion of vIL-10 protein (284.4±358.2 versus
181.9±130.2pg/mg protein, NS). The biodistribution of the vector
genome beyond the site of injection was determined by RT-PCR,
vIL-10 transcript was found in five out of 29 spleens.
Conclusion: These data support AAV-tetON-vIL10 as a valuable
approach for anti-inflammatory gene therapy in RA.
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Development of lentiviral vectors for gene therapy
of arthritis
M Militello*, F Apparailly†, Y-L Lin*, C Mettling*, C Jorgensen†‡,
P Corbeau*§
*Institut de Génétique Humaine CNRS UPR1142; †INSERM U475;
‡Service d’Immuno-Rhumatologie de l’Hôpital Lapeyronie; §Laboratoire
d’Immunologie de l’Hôpital Saint Eloi, Montpellier, France
The delivery to joints of genes able to inhibit inflammation and bone
loss represents an attractive therapeutic strategy in arthritis.
Arthritis Research    Vol 3 Suppl 1 Second International Meeting on Innovative RheumatologyHowever gene transfer into synoviocytes is limited by the fact that
these cells are naturally nonproliferative. As lentiviral vectors are
capable of transducing nondividing cells, contrary to the other
retroviral vectors, they could represent an interesting solution.
Moreover, the recent description of the role in viral DNA nuclear
import of a central DNA flap in HIV-1 genome allows the construc-
tion of HIV vectors with an increased capacity to introduce genes
into nondividing cells. Therefore, we tested such a vector ex vivo
on human synoviocytes, either nontreated, or growth-arrested by
the addition of aphidicolin, or treated with the reverse transcriptase
inhibitor AZT. An adenoviral vector was used as positive control,
and a murine retroviral vector as negative control. Table 1 shows
that the HIV vector, contrary to the control murine retroviral vector,
was able to transduce synoviocytes, even in absence of cell divi-
sion. Lentiviral vectors, that induce no inflammation and are stably
integrated, could represent an interesting tool for gene therapy of
arthritis. In vivo results will be presented.
Table 1
Titer
(transducing Synoviocytes/
units/ml) Synoviocytes aphidicolin Synoviocytes/AZT
HIV vector 1.4 × 106 4.5 × 105 <5 × 103
Murine <5 × 103 7.5 × 103 <5 × 103
retroviral vector
Adenoviral vector 1.0 × 107 1.3 × 107 1.0 × 107
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Factors influencing adenoviral gene transfer
TWJ Huizinga*, P Goossens*, E Pieterman*, R Vogels†,
M Havenga†
*Department of Rheumatology, Leiden University Medical Center,
Leiden, The Netherlands; †Crucell BV, Leiden, The Netherlands
Intra-articular injection of an adenoviral vector in nonhuman pri-
mates with arthritis results in effecient gene transfer of the synovio-
cyte like fibroblasts, whereas no gene transfer has been observed
to cartilage cells (Goossens et al: Hum Gene Ther 1999). In
humans a possible factor that may influence gene transfer are pre-
existing antibodies to adenovirus. Now, we have demonstrated that
70% of the synovial fluid samples harvested from 53 different
patients inhibited gene transfer of adenovirus.
In 10 samples this was studied in detail by fractionation of the syn-
ovial fluid samples. The fraction that inhibited gene transfer most
strongly had a molecular mass of 150kDa and could be purified by
protein-A sepharose columns, strongly suggesting that this fraction
consisted of antibodies. In order to avoid the influence of naturally
occurring autoantibodies we tested if different types of aden-
oviruses (Ad5, Ad26, Ad34, Ad35 and Ad48) were inhibited as
strongly as Ad5. Only 4% of the synovial fluid samples contained
antibodies that inhibited Ad35-mediated gene transfer. Next we
tested if a vector that contained a fiber from subgroup B (Ad 11,
16 or 35) was as efficient in transducing synoviocytes as the origi-
nal Ad5 vector. The Ad5-fib35 vector encoding luciferase was
about 10 times as efficient than the wild-type fiber when similar
particle concentration was used to infect synoviocytes.
In conclusion, the current data suggest that fib35 is efficient in the
binding of an adenoviral vector to synoviocyte-like fribroblasts, and
that very few RA patients have naturally occurring antibodies to the
type 35 adenoviral vector.
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Induction of synovial apoptosis by gene transfer
and peptide mediated protein transduction
TJ Oligino*, Q Yao*, S Wang*, JC Glorioso*, CH Evans†,
SC Ghivizzani†, R Takate‡, R Barton‡, PD Robbins*
*Department of Molecular Genetics and Biochemistry, University of
Pittsburgh, Pittsburgh, PA, USA; †Center for Molecular Orthopaedics,
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,
USA; ‡Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA
The destruction of articular cartilage and bone due to pannus for-
mation is one of the more clinically challenging problems associ-
ated with rheumatoid arthritis. While synovectomy, the physical
removal or killing of synovial tissue, has demonstrated the ability to
delay the degradation of the rheumatoid joint the various methods
available for this procedure are either highly invasive or are associ-
ated with side effects. In order to combat these problems we have
been developing a biological synovectomy technique based on the
induction of apoptosis. Our approach has focused on the delivery
of pro-apoptotic proteins to the diseased synovium either through
gene transfer or direct peptide mediated protein delivery. Utilizing a
rabbit model of RA we have examined the effects of over express-
ing a number of proapoptotic proteins (p53, FasL, TRAIL,
granzyme B and activated caspase 3) in the cells of the synovial
lining. These experiments have demonstrated that the over expres-
sion of all of these proteins induce apoptosis in the synovial layer,
albeit to differing extents. Intra-articular delivery of adenoviral
vectors encoding the proapoptotic genes or proteins fused to
peptide transduction domains results in extensive apoptosis in the
cells of the synovial lining within 24h after vector delivery. The
induction of apoptosis in the synovium is also associated with a
decrease in the inflammation observed in the treated joints. The
magnitude of the reduction in leukocytic infiltration correlates
directly with the extent of apoptosis induced. These data suggest
that the over expression of proapoptotic proteins in synovium may
have applications in the treatment of RA.
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Targeted adenoviral vectors
E Vigne, A Brie, K Martin, A Gillardeaux, P Opolon,
M Perricaudet, M Latta-Mahieu, JF Dedieu, P Yeh
Aventis Gencell-CNRS-IGR UMR1582, Institut Gustave Roussy,
94805 Villejuif Cedex, France; Aventis Gencell, Centre de
Recherches de Paris, 94403 Vitry-sur Seine, France
Subgroup C human adenoviruses (Ad2 or Ad5) can transduce a
wide array of dividing and quiescent adherent cell types in vitro and
in vivo, essentially because their primary receptor (CAR) is widely
expressed at the cellular surface. On the other hand, specific target
cell types (eg some tumor cells, smooth muscle cells, fibroblasts)
display limiting amounts of the CAR receptor so that large viral
doses are needed for efficient infection, a constraint which favors
vector dissemination in vivo, even after loco-regional injection. Abro-
gating the native virus-CAR interaction while allowing the virus to
use a CAR-independent pathway for entry would thus represent a
major milestone in order to better control the vector tropism in vivo.
Towards this goal, we first engineered a series of capsid-modified
adenoviruses by genetically inserting targeting peptides within pro-
truding loops of the fiber and hexon capsid monomers (Vigne E,
et al: J Virol 1999, 73:5156). The most interesting virus – AE43 –
displays within the fiber HI loop a vitronectin-derived high affinity
peptide for the urokinase-type plasminogen activator (uPAR or
CD87), a cell surface receptor upregulated during cellular activa-
Available onlinehttp://arthritis-research.com/supplements/3/S1tion, and which controls cellular migration and invasion. Most inter-
estingly, AE43 could increase transduction of cells normally refrac-
tory to adenovirus infection more than 100-fold in vitro. We could
also demonstrate that AE43 retained its ability to enter the cell via a
CAR-dependent pathway in vitro, and displayed a normal tropism
following systemic injection in mice. To cripple the virus-CAR inter-
action, we then evaluated various strategies, including the introduc-
tion of CAR-ablating mutations within the fiber, and the shortening
of the fiber shaft. Interestingly, some of these constructs could
decrease transduction of CAR-positive cells at least 10-fold in vitro,
with a similar reduction in liver transduction following systemic injec-
tion in naïve mice. We are currently assessing the effect of combin-
ing within a single vector the uPAR-binding peptide of AE43 with
our best CAR-ablating mutations.
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A member of the T-box family of transcription
factors mediates cartilage formation in
mesenchymal progenitors C3H10T1/2
A Hoffmann*, S Czichos*, C Kaps*, D Bächner*, H Mayer*,
BG Kurkalli†, Y Zilberman†, D Gazit†, G Gross*
*Osteogenesis Group, Gesellschaft für Biotechnologische Forschung
(GBF), Mascheroder Weg 1, 38124 Braunschweig, Germany;
†Molecular Pathology, Hebrew University, Jerusalem, Israel
The bone morphogenetic protein 2 (BMP2)-dependent onset of
osteo-/chondrogenic differentiation in the acknowledged pluripotent
murine mesenchymal progenitor cell line C3H10T1/2 is accompa-
nied by the immediate upregulation of fibroblast growth factor recep-
tor 3 (FGFR3) and by a delayed upregulation of FGFR2. This direct
FGFR3-mediated expression seems to be essential for the onset of
chondrogenesis since the forced expression of activated FGFR3 is
sufficient for differentiation into the chondrogenic lineage. The
screening for FGFR3-regulated transcription factors exhibiting a
chondrogenic capacity in C3H10T1/2 indentified a T-box containing
transcription factor. Forced expression of this factor is sufficient for
the initiation of chondrogenic differentiation in mesenchymal progeni-
tors C3H10T1/2 in vitro. Implantation of these recombinant progeni-
tors at ectopic intramuscular sites of the mouse was followed by
massive cartilage formation substantiating the chondrogenic poten-
tial of this transcription factor. A potential role for this T-box factor in
chondrogenesis is also suggested by its expression in various skele-
tal elements at late stages of murine embryonic development as
demonstrated by in situ hybridization. These studies indicate that
BMP2 triggers onset of FGFR3-dependent signaling in mesenchy-
mal progenitors C3H10T1/2 to induce a novel type of transcription
factor for the initiation of chondrogenic differentiation.
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Adenoviral-based overexpression of TIMP-1
reduces tissue damage in the joints of TNF-a a
transgenic mice
G Schett, S Hayer, M Tohidast-Akrad, B Jahn-Schmid, S Lang,
F Kainberger, G Kollias, AC Newby, Q Xu, G Steiner, JS Smolen
Division of Rheumatology, Department of Internal Medicine III,
University of Vienna, Austria; Department of Molecular Genetics,
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Bristol, UK; Institute for Biomedical Aging Research, Austrian
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Chronic inflammation frequently entails the remodelling and/or
destruction of the involved tissues. This is illustrated by human dis-
eases and animal models characterized by TNF-a overexpression,
such as rheumatoid arthritis and TNF-a transgenic mice, in which
severe joint destruction is spontaneously observed in conjunction
with chronic synovial inflammation. The detailed molecular mecha-
nisms of TNF-a-mediated tissue damage are, however, unknown.
Since matrix metalloproteinases are among the molecules acti-
vated by TNF-a we hypothesized that overexpression of their
natural inhibitor, tissue inhibitor of metalloproteinases (TIMP)-1, in
TNF-a-transgenic mice, could inhibit the development of destruc-
tive arthritis. Such adenoviral-based overexpression of TIMP-1
strongly inhibited spreading of inflammation and bone resorption,
whereas treatment with the LacZ-control vector had no effect. This
inhibition of tissue remodelling and damage by TIMP-1 was also
associated with a significant reduction in clinical signs of arthritis
and prevention of development of autoimmune phenomena. We
conclude that matrix metalloproteinases are major effector mole-
cules of TNF-a-triggered tissue damage and that the highly effec-
tive inhibition by TIMP-1 should be considered in the treatment of
human disease.
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Therapeutic targeting of osteoclasts by
osteoprotegerin and bisphosphonates leads to a
reduction of TNFa a-mediated bone resorption
K Redlich, S Hayer, CR Dunstan, M Tohidast-Akrad, S Lang,
G Kollias, G Steiner, JS Smolen, G Schett
Division of Rheumatology, Department of Internal Medicine III,
University of Vienna, Austria; Department of Pathology, Amgen, Inc,
CA, USA; Department of Molecular Genetics, Hellenic Pasteur
Institute, Athens, Greece
Rheumatoid arthritis (RA) is characterized by a cytokine-triggered
chronic inflammation and the progressive destruction of bone.
TNF-a has been recognized as a crucial inflammatory signal in
RA; however, its influence on the destruction of bone is less
clear, although it may involve the formation of osteoclasts. In this
study, using a TNF-a transgenic mouse model, the effects of
osteoclast-targeted therapies, such as osteoprotegerin and
pamidronate, were examined on joint inflammation and bone
destruction. Mice were divided into five groups receiving either
osteoprotegerin, pamidronate, a combination of both agents,
infliximab, as a positive control, or phosphate-buffered saline, as
a negative control. Treatment was initiated at the onset of arthri-
tis, continued over 6 weeks, and thereafter the clinical, radiologi-
cal and histological outcomes were assessed. A significant
improvement of clinical symptoms, as assessed by the reduction
of paw swelling was only found in the infliximab group, whereas
all other treatment groups failed to show a significant improve-
ment. However, when assessing structural damage by X-ray
analysis, a significant retardation of joint damage was evident in
animals treated with osteoprotegerin the combination therapy of
osteoprotegerin and pamidronate, and also with infliximab,
whereas the reduction of radiologic damage in the pamidronate
group was evident, albeit not significant. Quantitative histologic
analysis revealed a significant reduction in the size of bone ero-
sions in all treatment groups when compared to the control
group. These data suggest that osteoprotegerin alone or its com-
bination with bisphophonates are effective therapeutical tools to
prevent TNF-a-mediated destruction of bone.
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Gene therapy for cartilage healing
SC Ghivizzani*, TJ Oligino†, E Gouze-Decaris*, G Palmer*,
PD Robbins†, CH Evans*
*Center for Molecular Orthopaedics, Harvard Medical School, Boston,
MA 02115, USA; †University of Pittsburgh School of Medicine,
Pittsburgh, PA 16219, USA
Articular cartilage has only a limited capacity for repair. Only in the
event of damage that extends through to the underlying vascula-
ture and marrow of the subchondral bone will a repair response be
initiated; populations of mesenchymal stem cells infiltrate the lesion
and synthesize space-filling tissue. This repair tissue is of inferior
composition and degenerates with time. Gene transfer strategies,
however, may provide methods to stimulate these cells toward the
synthesis of more suitable repair tissue that is functionally closer to
normal articular cartilage. Through the in vitro transfer of genes
encoding certain growth factors such as transforming growth
factor-b (TGF-b), insulin-like growth factor 1 (IGF-1) and bone mor-
phogenetic protein 2 (BMP-2) we have found it possible to stimu-
late chondrogenesis of bone marrow stem cells as well as increase
the synthesis and deposition of extracellular matrix components by
chondrocytes. In contrast to the exploration of complex ex vivo
methods for engineering cartilaginous tissues, we have been
undertaking practical methods for transferring genes encoding
chondrogenic growth factors directly to cells infiltrating osteochon-
dral defects in a rabbit model. For this approach, vectors suitable
for gene delivery in vivo are absorbed into a biologically compatible
matrix and implanted directly into freshly generated osteochondral
lesions. Using either recombinant adenoviral vectors or plasmid
DNAs we have shown that cells entering the defect can infiltrate
the implanted matrix, interact with the vector and express the trans-
gene product for up to 3 weeks. This method is currently being
evaluated for its effectiveness in repairing osteochondral defects
following the delivery of chondrogenic genes such as TGF-b,
BMP-2 and IGF-1.
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Transfer and intra-articular expression of the
IL-1Ra cDNA in human rheumatoid joints
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MC Wasko‡, M Tomaino§, R Kang§, TA Muzzonigro§, EM Elder¶,
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Biology & Anatomy, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
Permission was received from NIH and the FDA to undertake a
phase I clinical study to determine the safety and feasibility of the
retroviral, ex vivo transfer of a human IL-1Ra cDNA to human
rheumatoid joints. Eligible patients were post-menopausal females
with end-stage RA requiring replacement of the metacarpopha-
langeal (MCP) joints of one hand and also requiring surgery on at
least one other joint. The latter surgery provided the opportunity to
recover autologous synovial tissue from which to establish synovial
cell cultures. Half of each patients’ cells were transduced with the
retrovirus MFG-IRAP, while the other half remained as untrans-
duced controls. After safety testing of both sets of cells, the autolo-
gous synoviocytes were injected into the subjects’ MCP joints; in a
double-blinded manner, two joints received the genetically modi-
fied cells, and two joints received control cells. One week later, all
four MCP joints were surgically removed during joint replacement
surgery and the retrieved joint tissues analyzed for transgene
expression. Nine patients were treated in a dose-escalation
manner, receiving from 106–107 cells per MCP joint.
All patients tolerated the procedure well, and no adverse events
related to the study were reported. Transcripts originating from the
transgene were detected by RT-PCR in all joints that received
genetically modified cells, but in only one of the control joints.
Analysis of certain samples by in situ hybridization and immunohis-
tochemistry confirmed that cells expressing the transgene were
located in clumps on the synovial surface. Synovial cells were
recovered from the retrieved tissues and placed into cell culture.
Concentrations of IL-1Ra were higher in media conditioned by
cells recovered from genetically modified joints than in media con-
ditioned by cells from control joints. Although the design of the
study precluded assessment of clinical efficacy, several patients
reported symptomatic improvement; this was attributed to a
placebo effect.
These data confirm that it is possible to transfer genes to human,
arthritic joints and to express those genes intra-articularly in a
manner that is safe and acceptable to patients. This encourages
further development of gene therapies for the treatment of arthritis
in humans.
Acknowledgement: Supported by grant number RO1 AR43623
from NIAMS.
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The delivery of antiarthritic genes to the synovial lining of joints is
an effective strategy for the treatment of experimental models of
rheumatoid arthritis (RA). Moreover, in two clinical studies it has
proved possible to transfer the human interleukin-1 receptor antag-
onist (hIL-1Ra) cDNA to human rheumatoid joints. These protocols,
however, utilized an ex vivo approach to gene delivery. While
useful for establishing proof of concept, ex vivo methods do not
lend themselves well to widespread clinical application. For this
reason, we are devoting increasing attention to developing clini-
cally acceptable in vivo methods of gene delivery to synovium.
Because chronic conditions such as RA will probably require
extended periods of intra-articular gene expression, integrating
vectors are more attractive. In preclinical experiments, two such
vectors, adeno-associated virus and high-titer Moloney-based
retrovirus, have shown promise for in vivo gene delivery to syn-
ovium. Lentiviral vectors also possess favourable properties in this
regard, but there are no published data on their suitability for in
vivo gene delivery to joints. Here we report preliminary data from
the use of lentiviruses to deliver genes to articular tissues.
The recent generation of packaging systems able to produce high
titers of replication-incompetent HIV-based retroviruses, and the
pseudotyping of lentiviral vectors with the vesicular stomatitis virus
G-protein (VSV-G) which increase the target cell range and allow
concentration by centrifugation have facilitated these studies. In
culture we have found that human synoviocytes, and both human
and rat chondrocytes were efficiently transduced by high titer
(>109pfu/ml) of VSV-G pseudotyped HIV-1-based lentiviral
vectors containing the b-galactosidase gene (lacZ). Similar pat-
terns of expression were observed using rabbit synovial fibroblast
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cells. Direct, intra-articular gene delivery was performed by inject-
ing similar lentiviral preparations into the knees of Wistar rats. His-
tological analyses of the knee joints revealed the expression of lacZ
in the synovial membrane for at least one week following injection.
No lacZ staining was observed following the injection of empty
viruses. Based on the ability to successfully deliver and express the
lacZ marker gene in synoviocytes in culture and in the synovial
lining in vivo, a recombinant vector containing hIL-1Ra has been
constructed and is being evaluated.
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In chronic joint diseases, inflammation causes an imbalance in car-
tilage matrix turnover shifting towards degradation. This process
may be promoted by destructive invasion of synovial tissue into
cartilage as well as a switch in chondrocyte physiology. Further-
more, we could demonstrate a decrease in the expression of mor-
phogenic factors, which are possibly supporting homeostasis and
are probably released by the synovium in its function as cartilage
nursing tissue. Leading to progressive degradation and loss of the
cartilaginous joint surface, chronic joint diseases eventually
depend on replacement therapies.
In recent years, methods for biological reconstruction of the articu-
lar surfaces with engineered cartilage transplants evolved as an
alternative to the established therapy of endoprosthetic arthro-
plasty. The basic principle of the various strategies is the delivery
and integration of functionally active autologous chondrocytes or
mesenchymal precursor cells within an appropriate carrier system
further supported by differentiation promoting factors into the origi-
nal anatomic site to restore tissue architecture and function.
Using  in vitro preformed implants appears to be particularly
promising. This cartilage engineering is usually based on applica-
tion of biocompatible and resorbable embedding substances
and/or scaffold materials. Results from gene expression analysis
clearly favour three-dimensional instead of monolayer chondrocyte
cultivation to enhance cartilage matrix production in vitro. Implants
of such constructs in the cartilaginous environment of the joint in
rabbits or horses were found to produce cartilage typic morpholog-
ical patterns and matrix synthesis. Heterotopic implantation for
example subcutaneously into immunocompromized nude mice may
induce unspecific fibroblastoid invasion and implant destruction.
Encapsulation experiments prevented this process of infiltration,
leading to enhanced matrix production and cartilage formation.
As an alternative and avoiding artificial barriers, tissue maturation
and stabilization may be supported by morphogenetic factors,
which are representatives of the TGF-b family and key molecules in
cartilage and joint formation during development. Clonally
expanded bone morphogentic protein (BMP)-7 transgenic primary
chondrocytes demonstrated a qualitative switch in collagen expres-
sion from type I towards type II when cultured in alginate beads.
Other markers of chondrocyte dedifferentiation were down-regu-
lated also. Implantation subcutaneaously into nude mice revealed
almost complete exclusion of host fibroblasts from the engineered
cartilage accompanied by improved implant maturation.
Thus, the present results demonstrate that current artificial carti-
lage transplants are already feasible for joint cartilage repair. Nev-
ertheless, treatment of severe joint defects faces specific
problems, which are continuously addressed in ongoing studies:
the fixation and integration of engineered cartilage in joints; the
transplant protection against chronic inflammatory degradation;
and the required enormous mechanical stability.
These challenges are particularly addressed by the current devel-
opments of composite grafts consisting of bone and cartilage com-
ponents for reconstruction of the subchondral bone. Furthermore,
controlled use of morphogenetic growth factors will unfold great
potential to stabilize transplants, promote regeneration and may
also allow guided tissue repair starting from mesenchymal precur-
sors or stem cells.
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Autologous bone marrow grafting of avascular
osteonecrosis before collapse
P Hernigou
Hôpital Henri Mondor, 94000 Créteil, France
Introduction and method: To enhance the rate of bone repair,
injection of bone marrow in the necrosis was done during core
decompression. The source of bone marrow was the iliac crest. A
quantity of 150ml was obtained by bone marrow aspiration. The
whole marrow was concentrated using centrifugation to increase
the cell concentration in an aliquot of 25ml. Bone marrow was
injected in the necrosis and in the femoral head by the hole of the
core decompression. 42 hips with MRI avascular necrosis without
collapse (stage 11) were operated with this technique between
1991 and 1993. The average follow up is 5 years.
Results: Five hips are now failures (collapse) with a stage III at the
last revision. The other hips are pain free and stage Il. The postop-
erative MRI demonstrates a modification of the signal in most
cases and a disparition of the necrosis in four cases. The number
of transplanted cells was calculated in a laboratory study; the
number of nucleated cells was counted in the marrow transplanted
and the fibroblast colony forming cells (CFU-F) were cloned to
appreciate the activity and the number of progenitor in the marrow
transplanted ; failures of this technique (five hips with stage 3)
occurred in patients with a low number of transplanted cells
(average 2000 CFU-F for failures and average 25000 CFU-F for
the other hips).
Conclusion: Many different grafts have been used in avascular
necrosis to provide structural support or to enhance bone forma-
tion. Since bone marrow contains progenitor cells it may be associ-
ated to core decompression. It is a simple and easy adjuvant to
core decompression.
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home to the inflamed joints and suppress
collagen-induced arthrtis
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C Garrison-Fathman*
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Objective: Autoantigen-specific T cells have tissue-specific
homing properties, suggesting that these cells may be ideal vehi-
cles for the local delivery of ‘immunoregulatory molecules’. We
tested this hypothesis by using type II collagen (CII)-specific CD4’
T hybridomas, or prim CD4’ T cells following gene transfer as vehi-
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gen-induced arthritis (CIA).
Method: CII-specific T cells were transduced to express IL-12
antagonist IL-12 p4O, using retroviral vectors, and were trans-
ferred into CIA mice. To directly examine whether CII-specific
T cells home to the site of inflammation, we transduced a GFP-
luciferase fusion protein gene into CII-specific T cells and tested
the patterns of cell trafficking using whole-body bioluminescence.
Results: Transfer of CII-specific IL12 p4O producing CD4’+T cells
after primary immunization significantly inhibited the development
of CIA. The beneficial effect of IL-12 p4O-transduced T cells for
CIA requires TCR spcificity against CII. Using bioluminescence,
we found that CII-reactive T cell hybridomas accumulated and
remained in inflamed joints when transferred into CII-immunized
arthritic mice.
Conclusion: These results indicated at the local delivery of
IL12p4O by T cells inhibited CIA by suppressing an autoimmune
response at the site of inflammation. We conclude that modifying
antigen-specific T cells by retroviral transduction for local expres-
sion of regulatory proteins is a promising therapeutic strategy for
the treatment of RA.
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Objective: Rheumatoid arthritis (RA) is an autoimmune arthritis for
which treatment options remain limited. Pathogenic mechanisms of
RA and its animal model collagen-induced arthritis (CIA) involve
joint infiltration by pro-inflammatory T-helper 1 (Thl) type CD4+
T-cells. This study investigated the potentiel use of retrovirally
transduced collagen type II (CII)-reactive CD4+ T-cells for local
delivery of an anti-inflammatory cytokine, interleukin 4 (IL-4), to
inflamed joints.
Method: CII-specific CD4+ T-cell hybridomas (made from CII-spe-
cific TCR transgenic mouse T cells) were transduced with a retrovi-
ral vector encoding IL-4 and the marker yellow fluorescent protein
(YFP) in a bicistronic IRES containing construct. Transduced
hybridomas were sorted based on YFP expression and injected
intravenously into immunized male DBA/lLacJ mice prior to disease
onset. For bioluminescence imaging, IL-4 expressing T cell hybrido-
mas were transduced with luciferase expressing retroviral con-
structs.
Results: Adoptive transfer of transduced hybridomas, that consti-
tutively expressed the transgenes, significantly decreased mean
disease severity by reducing the number of inflamed joints. Biolu-
minescence studies showed that the hybridomas migrated to,
accumulated in, and were retained in the inflamed joints. There
were no significant changes in the cytokine milieu of the draining
lymph nodes nor in the systemic levels of the anti-collagen anti-
body subtypes IgGl and IgG2a in treated mice.
Conclusion: The beneficial clinical effects observed in our model
were most likely based on the local actions of IL-4 in the inflamed
joints. The local delivery (and effects) of regulatory cytokines like
IL-4 constitute a novel and effective method of treating organ-spe-
cific auto-immune diseases and of minimizing the systemic adverse
effects of immune-modulating therapy.
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osteoarthritis
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Osteoarthritis (OA), the most common form of joint disease, repre-
sents a clinical classification of pathological conditions involving
progressive degradation of articular cartilage and remodeling of
subchondral bone. Genes whose products are involved in chon-
drogenesis and osteogenesis starting from the common progenitor
cells, genes determining the terminal differentiation of chondro-
cytes and genes whose products trigger breakdown of the carti-
laginous matrix are obvious candidates for therapeutic intervention.
In this study we used human articular cartilage primary cells to
conduct a series of gene expression profiling experiments. The
cells were subjected to various treatments, which mimic OA initia-
tion and development: IL-1ß-FAD (FGF-2+Dexamethasone+Ascor-
bic acid) and mechanical stress. The gene expression profiles
corresponding to various applied treatments were studied by
microarray hybridization and analyzed by QBI’s proprietary bioinfor-
matics tools. The obtained gene expression patterns indicates that
the chosen in vitro cell system accurately reflects the processes
that occur in OA joints in vivo since many genes known to be
markers of OA were identified by us as displaying the expected
type of behavior. After performing the full analysis of hybridization
results, a list of 254 genes was obtained. Among them are 210
known genes and 44 novel ones. Out of them 80 genes were
further analyzed by in situ hybridization on sections obtained from
OA patients and control group and by RT-PCR. 15 genes have
shown promising results. Among them, genes whose expression
was upregulated in chondrocytes located close to the eroded
surface of the OA articular cartilage, in osteoprogenitor cells and in
endothelial cells. Further studies are being conducted to analyze
the role of these genes in OA.
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electroporation in rat patellar chondrocytes
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*UMR 7561 CNRS-Nancy I, BP 184, F 54505 Vandoeuvre, France
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Objective: The use, via electro-permeabilization (electroporation),
of ‘chondroprotective’ genes may provide a powerful set of tools
applicable to the development of plasmid-based gene therapies for
OA process. To assess whether permeabilizing drug pulses may
overcome the barrier-effect of peri-cellular matrix environment, we
investigated the efficiency of plasmid delivery by electroporation
and the subsequent duration of transgene expression (GFP and
Hsp-70) in rat patellar cartilage.
Methods: The expression vector (pcDNA3.1/CT-GFP) was used
to clone the nucleic acid sequence of rat Hsp-70. Empty vector
and plasmid carrying the Hsp-70 cDNA were then prepared
according to standard procedures. After anesthesia, plasmids
were directly injected into both rat knees and transcutaneous elec-
tric pulses were then immediately applied (day 0). Expression of
GFP and Hsp-70 in rat patellae was studied by immuno-histo-
chemistry from day 2 to 3 months.
Results: On Day 2 after electric pulses, the percentage of GFP
positive chondrocytes was about 30% in the superficial cartilage
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layer and 60% in the deep layer respectively. No staining was
depicted in the intermediate layer. After 3 months, long-term
expression of GFP in rat patella was only present in chondrocytes
localized in the deep layer (20% of transfected cells). In addition,
electric pulses did not alter cartilage structure or metabolism, as
assessed by histological evaluation (HES and toluidine blue) and
radiolabeled sulfate incorporation. Immuno-staining confirmed the
expression of Hsp-70 in a similar pattern than GFP, as observed
with the empty vector.
Conclusions: Gene transfer approach, based on the use of elec-
tric pulses, is an easy, safe and rapid method that can be used for
the direct gene delivery to rat patellar chondrocytes. This method
allows targeting of chondrocytes located in the deep layers of car-
tilage.
Acknowledgement: Supported by a grant of GIP Fonds de
Recherche HMR.
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Objective: Cartilage hypocellularity due to cell death contributes to
the development of OA. Experimental exposure to MIA results in
either chondrocyte necrosis (in vitro) or experimental OA with
apoptosis when injected ia (in vivo). As Hsp-70 is known to
protect from cell death, we have evaluated the beneficial properties
of its over-expression or induction in rat chondrocyte cells (RCC)
after MIA exposure.
Methods: Cloning rat Hsp-70 cDNA sequence into the plasmid
pcDNA3.1/CT-GFP and transfection led to over expression of
Hsp-70 with PEI agent. RT-PCR and Western blotting then moni-
tored expression level of Hsp-70. In vitro and in vivo exposure of
RCC to the proteasome inhibitor MG132 dramatically enhanced
the induction of Hsp-70. Protection against MIA toxicity was
analysed either after transfection of RCC with the vector or after
pre-treatment of RCC with MG132. Cytotoxicity of MIA was evalu-
ated by MTT and LDH tests. In vivo assay: on day 0, Wistar rats
were injected ia with MG132, 2 hours before ia injection of MIA
(0.3 and 0.03 mg). On Day 15, knees and patellae were carefully
dissected for histological assessment.
Results: In vitro MIA exposure led to cell death, rather by necrosis
than by apoptosis (8%). Over-expression of Hsp-70 significantly
protected from MIA toxicity in transfected cells after 24 and 48
hours respectively (28 and 64%). Moreover, preventive and cura-
tive MG132 (1.5 µM) pre-treatments preserved, at least in part,
RCC from MIA chondrotoxicity in a dose-dependant manner
related to the magnitude of Hsp-70 induction. In vivo, macroscopi-
cal evaluation of knees exposed to MIA demonstrated that MG132,
when injected ia preventively, diminished the severity of OA-like
chondral lesions on Day 15.
Conclusions: In vitro, the over-expression (gene transfer) or the
induction (MG 132) of Hsp-70 protects RCC from MIA cytotoxic-
ity. Induction of Hsp-70 in vivo with MG 132 could be promising to
modulate OA process and needs to be confirmed in rat experimen-
tal OA-models by using gene therapy (viral or non-viral).
Acknowledgement: Supported by a grant of GIP Fonds de
Recherche HMR.
P42
High efficiency intramuscular plasmid
electrotransfer: application for sustained
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D Scherman, M Bettan, V Deleuze, P Kreiss, M Bureau
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Gene delivery to skeletal muscle and to tumors is a promising strat-
egy for the treatment of muscle disorders or cancer, and for the
systemic secretion by muscle of therapeutic proteins. We and
others have reported efficient plasmid DNA transfer into muscle
fibers using square-wave electric pulses of low field strength and
of long duration [1–5]. This i.m. plasmid ‘electrotransfer’ method
increases reporter and therapeutic gene expression by several
orders of magnitude in various muscles and species, and
decreases inter-individual variability. We will present recent results
concerning the plasmatic secretion after i.m. gene electrotransfer
of a reporter protein, human secreted alkaline phosphatase, which
was sustained for more than 12 months. Factor IX was also
detected at high concentration in the systemic circulation after i.m.
plasmid electrotransfer. Intramuscular electrotransfer of an EPO-
encoding plasmid led to a several-months stable hematocrit
increase. Moreover, EPO seretion also led to phenotoypic correc-
tion in a murine model of beta-thalassemia. Finally, electrotransfer
of a murine IL-10-encoding plasmid was shown to induce a signi-
ficative, but transient increase in circulating IL-10. This had a pro-
tective role in atherosclerosis, achieving 60 % reduction in lesion
size, and also modulated VEGF expression and neoangiogenesis in
a model of hindlimb ischemia.
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